Announcement • Jun 23
PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on July 15, 2026 PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 52.0000 per share payable on July 15, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Announcement • May 12
PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026 PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026. Buy Or Sell Opportunity • May 04
Now 63% undervalued The stock has been flat over the last 90 days, currently trading at €0.0005. The fair value is estimated to be €0.0013, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 25% over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 1.2% in a year. Earnings are forecast to grow by 4.1% in the next year. Reported Earnings • May 02
First quarter 2026 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2025) First quarter 2026 results: EPS: US$0.001 (up from US$0 in 1Q 2025). Revenue: US$95.2m (up 37% from 1Q 2025). Net income: US$18.8m (up 131% from 1Q 2025). Profit margin: 20% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is expected to decline by 4.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Apr 10
Now 38% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to €0.026. The fair value is estimated to be €0.042, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 1.2% in 2 years. Earnings are forecast to grow by 24% in the next 2 years. Recent Insider Transactions • Apr 07
Insider recently sold €552k worth of stock On the 31st of March, Theodore Rachmat sold around 14m shares on-market at roughly €0.039 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.4m. Insiders have been net sellers, collectively disposing of €4.6m more than they bought in the last 12 months. Buy Or Sell Opportunity • Mar 25
Now 34% undervalued after recent price drop Over the last 90 days, the stock has fallen 98% to €0.0005. The fair value is estimated to be €0.00076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to decline by 10% in 2 years. Earnings are forecast to decline by 0.7% in the next 2 years. Recent Insider Transactions • Mar 11
Insider recently sold €1.7m worth of stock On the 5th of March, Theodore Rachmat sold around 42m shares on-market at roughly €0.04 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Mar 09
Full year 2025 earnings released: EPS: US$0.002 (vs US$0.003 in FY 2024) Full year 2025 results: EPS: US$0.002 (down from US$0.003 in FY 2024). Revenue: US$295.0m (down 2.1% from FY 2024). Net income: US$40.3m (down 11% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). Revenue is expected to decline by 5.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.2%. Reported Earnings • Oct 23
Third quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 3Q 2024) Third quarter 2025 results: EPS: US$0 (down from US$0.001 in 3Q 2024). Revenue: US$62.8m (down 20% from 3Q 2024). Net income: US$6.46m (down 50% from 3Q 2024). Profit margin: 10% (down from 17% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 28
Second quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2024) Second quarter 2025 results: EPS: US$0 (down from US$0.001 in 2Q 2024). Revenue: US$68.0m (down 13% from 2Q 2024). Net income: US$6.72m (down 35% from 2Q 2024). Profit margin: 9.9% (down from 13% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.0%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • May 12
Now 67% undervalued after recent price drop Over the last 90 days, the stock has fallen 99% to €0.0005. The fair value is estimated to be €0.0015, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to decline by 6.1% in 2 years. Earnings are forecast to decline by 1.1% in the next 2 years. New Risk • May 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Apr 25
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Apr 24
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Announcement • Apr 22
PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on May 16, 2025 PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 10.0000 per share payable on May 16, 2025, ex-date on April 28, 2025 and record date on April 29, 2025. Announcement • Mar 04
PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025 PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025. Location: jakarta Indonesia Reported Earnings • Feb 24
Full year 2024 earnings released: EPS: US$0.003 (vs US$0.002 in FY 2023) Full year 2024 results: EPS: US$0.003 (up from US$0.002 in FY 2023). Revenue: US$301.4m (down 13% from FY 2023). Net income: US$45.2m (up 31% from FY 2023). Profit margin: 15% (up from 10.0% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 3Q 2023) Third quarter 2024 results: EPS: US$0.001 (up from US$0 in 3Q 2023). Revenue: US$78.5m (up 22% from 3Q 2023). Net income: US$13.0m (up 124% from 3Q 2023). Profit margin: 17% (up from 9.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is expected to decline by 6.8% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Oct 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Buy Or Sell Opportunity • Oct 10
Now 28% undervalued Over the last 90 days, the stock has risen 15% to €0.05. The fair value is estimated to be €0.069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Jul 16
Now 28% undervalued Over the last 90 days, the stock has risen 16% to €0.043. The fair value is estimated to be €0.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 6.6% in a year. Earnings are forecast to grow by 12% in the next year. Reported Earnings • Jul 14
Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 2Q 2023) Second quarter 2024 results: EPS: US$0.001 (up from US$0 in 2Q 2023). Revenue: US$77.8m (down 3.2% from 2Q 2023). Net income: US$10.4m (up US$9.52m from 2Q 2023). Profit margin: 13% (up from 1.1% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • May 13
Now 32% undervalued Over the last 90 days, the stock has risen 108% to €0.053. The fair value is estimated to be €0.078, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 7.6% in a year. Earnings are forecast to grow by 45% in the next year. Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2023) First quarter 2024 results: EPS: US$0.001 (up from US$0 in 1Q 2023). Revenue: US$73.8m (down 16% from 1Q 2023). Net income: US$10.2m (up 228% from 1Q 2023). Profit margin: 14% (up from 3.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. New Risk • Apr 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (10% net profit margin). Announcement • Feb 13
PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024 PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024. Reported Earnings • Feb 05
Full year 2023 earnings released: EPS: US$0.002 (vs US$0.009 in FY 2022) Full year 2023 results: EPS: US$0.002 (down from US$0.009 in FY 2022). Revenue: US$345.0m (down 53% from FY 2022). Net income: US$34.6m (down 75% from FY 2022). Profit margin: 10.0% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 2 years compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. New Risk • Jan 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 24% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risks Dividend is not well covered by earnings (116% payout ratio). Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Recent Insider Transactions • Dec 31
Insider recently bought €3.0m worth of stock On the 22nd of December, Garibaldi Thohir bought around 99m shares on-market at roughly €0.031 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Oct 20
Third quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 3Q 2022) Third quarter 2023 results: EPS: US$0 (down from US$0.003 in 3Q 2022). Revenue: US$64.5m (down 69% from 3Q 2022). Net income: US$5.79m (down 85% from 3Q 2022). Profit margin: 9.0% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.9%. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 129% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Aug 01
Now 29% undervalued after recent price drop Over the last 90 days, the stock is down 6.1%. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 29% in 2 years. Earnings is forecast to decline by 17% in the next 2 years. Reported Earnings • Jul 30
Second quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 2Q 2022) Second quarter 2023 results: EPS: US$0 (down from US$0.003 in 2Q 2022). Revenue: US$80.3m (down 58% from 2Q 2022). Net income: US$863.6k (down 98% from 2Q 2022). Profit margin: 1.1% (down from 21% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has increased by 112% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 30
First quarter 2023 earnings released: EPS: US$0 (vs US$0.002 in 1Q 2022) First quarter 2023 results: EPS: US$0 (down from US$0.002 in 1Q 2022). Revenue: US$87.8m (down 45% from 1Q 2022). Net income: US$3.11m (down 88% from 1Q 2022). Profit margin: 3.5% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 8.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 116% per year whereas the company’s share price has increased by 113% per year. Upcoming Dividend • Mar 21
Upcoming dividend of Rp45.00 per share at 0.5% yield Eligible shareholders must have bought the stock before 28 March 2023. Payment date: 05 April 2023. Payout ratio is a comfortable 4.8% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (5.8%). Reported Earnings • Feb 22
Full year 2022 earnings released: EPS: US$0.009 (vs US$0.001 in FY 2021) Full year 2022 results: EPS: US$0.009 (up from US$0.001 in FY 2021). Revenue: US$731.5m (up 141% from FY 2021). Net income: US$138.8m (up US$124.9m from FY 2021). Profit margin: 19% (up from 4.6% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 15% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.4%. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 80% per year, which means it is significantly lagging earnings growth. Announcement • Feb 11
PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023 PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023, at 15:00 SE Asia Standard Time. Announcement • Jan 04
PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir. PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir on January 2, 2023. The proceeds from private placement were used for this acquisition. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent President Commissioner Hamid Awaluddin was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 12
Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.001 in 3Q 2021) Third quarter 2022 results: EPS: US$0.003 (up from US$0.001 in 3Q 2021). Revenue: US$206.1m (up 103% from 3Q 2021). Net income: US$37.7m (up 100% from 3Q 2021). Profit margin: 18% (in line with 3Q 2021). Revenue is expected to decline by 5.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 28
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: US$191.9m (up 173% from 2Q 2021). Net income: US$41.0m (up US$58.1m from 2Q 2021). Profit margin: 21% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Jul 05
Now 31% undervalued after recent price drop Over the last 90 days, the stock is down 38%. The fair value is estimated to be €0.072, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years. Buying Opportunity • Jun 17
Now 20% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be €0.061, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years. Reported Earnings • Jun 01
First quarter 2022 earnings released: EPS: US$0.002 (vs US$0 in 1Q 2021) First quarter 2022 results: EPS: US$0.002 (up from US$0 in 1Q 2021). Revenue: US$159.0m (up 132% from 1Q 2021). Net income: US$25.9m (up 304% from 1Q 2021). Profit margin: 16% (up from 9.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 80%, compared to a 52% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 72% per year, which means it is well ahead of earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Ida Bagus Supancana was the last independent director to join the board, commencing their role in 2011. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Mar 09
Now 22% undervalued Over the last 90 days, the stock is up 131%. The fair value is estimated to be US$0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. The company has become profitable over the last year. Reported Earnings • Nov 27
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2021 results: EPS: US$0.001 (up from US$0.001 loss in 3Q 2020). Revenue: US$101.6m (up 261% from 3Q 2020). Net income: US$18.9m (up US$26.6m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 31
Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.001 loss in 2Q 2020) The company reported a decent second quarter result with improved revenues, although losses increased and control over costs was weaker. Second quarter 2021 results: Revenue: US$70.4m (up 114% from 2Q 2020). Net loss: US$17.1m (loss widened 120% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 148 percentage points per year, which is a significant difference in performance. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total losses of US$16.4m, with earnings decreasing by US$43.0m from the prior year. Total revenue was US$177.4m over the last 12 months, down 27% from the prior year. Announcement • Sep 21
PT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI Index PT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI Index